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Abstract
Background: Lyme neuroborreliosis (LNB) is one of the manifestations of Lyme disease. Although it is known that
immune reaction of LNB patients is dominated by Th1 and Th2 responses and patients have elevated numbers of B
cells in their cerebrospinal fluid (CSF), not all the cells involved in inflammation and cytokine secretion have been
characterized. The current diagnostics of LNB is based on intrathecal production of antibodies. In recent years, the
measurement of chemokine CXCL13 concentration from the CSF has been introduced as a new promising
diagnostic tool for LNB to complement the antibody-based diagnostic methods. A few other cytokines have also
been analyzed as possible diagnostic markers. However, multiplex analyses simultaneously evaluating the
concentrations of a large number of different cytokines in the CSF of LNB patients have been lacking thus far.
Extensive cytokine profiling CSF samples of LNB patients would also help in understanding the complex
immunopathogenesis of LNB.
Methods: CSF samples were analyzed from 43 LNB patients, 19 controls, 18 tick-borne encephalitis patients, and 31
multiple sclerosis patients. In addition, CSF samples from 23 LNB patients obtained after the antibiotic treatment
were examined. Altogether, the concentrations of 49 different cytokines were determined from all of the samples.
The concentrations of 48 different cytokines were analyzed by magnetic bead suspension array using the Bio-Plex
Pro Human Cytokine 21- and 27-plex panels, and the concentration of CXCL13 was analyzed by an ELISA based
method.
Results: Distinct cytokine profiles which were able to distinguish LNB patients from controls, tick-borne encephalitis
patients, multiple sclerosis patients, and LNB patients treated with antibiotics were identified. LNB patients had
elevated concentrations of all major T helper cell type cytokines (Th1, Th2, Th9, Th17, and Treg) in their CSF.
Conclusions: Despite the great differences in the CSF cytokine profiles of different patient groups, CXCL13 still
remained as the best marker for LNB. However, IL-1ra might also be helpful as a marker for the antibiotic treatment
response. Concerning the immunopathogenesis, this is the first report suggesting the involvement of Th9 cells in
the immune response of LNB.
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Background
Lyme disease is the most common vector-borne disease in
the Northern hemisphere. It is caused by Borrelia burgdor-
feri sensu lato spirochetes which are transmitted to humans
through the bite of an infected tick vector. B. burgdorferi
sensu lato group (later referred to as “borrelia”) comprises
of several different genospecies [1] of which B. burgdorferi
sensu stricto, B. afzelii, and B. garinii are the most common
disease-causing agents. Different genopecies of borrelia are
usually associated with different disease outcomes; for
example, B. garinii is considered to be the most common
cause of Lyme neuroborreliosis (LNB) in Europe [2]. The
symptoms of LNB appear within a few weeks after the bite
of an infected tick although, in rare cases, the development
of symptoms may take a few months or even years. LNB
patients may suffer, e.g., from lymphocytic meningitis, radi-
culoneuritis, and cranial neuritis [3, 4].
* Correspondence: kaisa.pietikainen@utu.fi
1Department of Medical Microbiology and Immunology, University of Turku,
Kiinamyllynkatu 13, FI-20520 Turku, Finland
2Turku Doctoral Programme for Molecular Medicine, Turku, Finland
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pietikäinen et al. Journal of Neuroinflammation  (2016) 13:273 
DOI 10.1186/s12974-016-0745-x
Immunopathology of LNB is not entirely understood.
Patients are defined as having elevated white blood cell
counts in their CSF with over 90 % of these cells being
lymphocytes [4, 5]. By analyzing cytokine production in
the cerebrospinal fluid (CSF) of LNB patients, it has
been demonstrated that immune reactions of the pa-
tients are characterized by a Th1 type response early in
the course of infection, and later during the disease, the
immune defense is accompanied by a Th2 response [6].
In addition to a T cell response, CSF of LNB patients
contains more B cells than the CSF of patients with
other central nervous system diseases [5, 7, 8]. However,
the role of other cell types in the immunopathology of
LNB is less evident and not all the cells involved in in-
flammation and cytokine secretion have been character-
ized. An extensive cytokine profiling of CSF samples of
LNB patients would lead to a deeper understanding of
the immunopathogenesis of LNB.
The diagnosis of LNB is based on the assessment of
neurological symptoms, B cell pleocytosis in the CSF, and
most importantly, intrathecal production of antibodies
against borrelia. Antibody-based diagnosis, however, has
limitations because antibodies are absent during the early
phase of the disease. Borrelia-specific antibodies may also
persist long after a patient has been treated which compli-
cates the discrimination of an acute reinfection from a
previously treated and cured disease [4].
Recently, measurement of the concentration of a che-
mokine CXCL13 in the CSF samples of suspected LNB
patients has been introduced as a new diagnostic tool
for the infection. CXCL13 levels of LNB patients are highly
elevated when compared with healthy controls or patients
suffering from other neurological conditions [9–17]. Also,
the levels of a few other cytokines have been studied in the
CSF of LNB patients [6, 8, 16, 18–24], but importantly, a
multiplex analysis of CSF samples of LNB patients includ-
ing a large panel of different cytokines has been lacking
thus far.
In this study, we compared the concentrations of
49 different cytokines among CSF samples of LNB
patients, non-LNB controls, and patients suffering
from other neurological conditions. Our main aims
were to gain new information on the immunopathol-
ogy of LNB and to identify new biomarkers for the
laboratory diagnostics of the infection. We also mea-
sured the CSF cytokine concentrations after antibiotic
treatment of LNB to evaluate the applicability of the
molecules as markers of treatment response. As a
result of the profiling, we identified distinct cytokine
profiles in the CSF of LNB patients which suggest the
involvement of B cells and all major T helper cell
types in the immunopathology of LNB. Chemokine




CSF samples used in this study were from patients identi-
fied retrospectively from the laboratory information-
management system of our laboratory. The samples were
from 43 LNB patients (samples drawn before the onset of
antibiotic treatment), 19 non-LNB control subjects, 18
tick-borne encephalitis (TBE) patients, and 31 multiple
sclerosis (MS) patients. LNB and TBE patients were diag-
nosed as previously described [9]. The non-LNB controls
were samples that were sent to our laboratory for borrelia
antibody analysis and that were found to be borrelia anti-
body negative. MS patients were clinically diagnosed cases
from the local university hospital. In addition, follow-up
samples obtained from 23 of the 43 LNB patients after the
antibiotic treatment (6–380 days) were analyzed. LNB
patients were treated with intravenous ceftriaxone and/or
oral doxycycline.
CSF samples were obtained from the patients by lumbar
puncture, sent to our laboratory at room temperature, and
stored at 4 °C until diagnostic assays were performed. After
the initial analyses, the samples were stored in −20 °C until
further usage.
Multiplex cytokine analysis
Cytokine levels in all CSF samples were determined by
magnetic bead suspension array using the Bio-Plex Pro
Human Cytokine 21- and 27-plex panels (Bio-Rad Labora-
tories, Hercules, CA, USA) as previously described [25–27].
The panels included the cytokines listed in Table 1.
Recombinant cytokines included in the kit were used
to generate standard curves for each analyte. Individual
concentration readings which remained below the meas-
uring range of the assay were given a value that corre-
sponded to a half of the lowest standard concentration
of the respective cytokine analysis, and on the other
hand, concentrations over the detection range were
given a value that was 1.5 times the highest concentra-
tion of the standard.
CXCL13 measurement
CXCL13 levels in the CSF samples were measured as
previously described [9] with a human CXCL13 kit
(Quantikine; R&D Systems, Minneapolis, MN, USA) ac-
cording to the manufacturer’s instructions. Samples with
a concentration below the standard curve of the assay
were given a value that corresponded to a half of the
value of the lowest point of the standard.
Statistical analyses
Continuous variables were characterized using medians
and range of values, and in case of categorical variables,
frequencies and percents were used. Mann-Whitney U
Pietikäinen et al. Journal of Neuroinflammation  (2016) 13:273 Page 2 of 10
test was used to test the difference in age between the
groups, and for sex, Pearson’s chi-squared test was used.
Differences in cytokine concentrations between patient
groups (LNB, non-LNB controls, TBE, and MS) were
tested using independent samples t test for logarithmic
transformed variables, and Bonferroni’s method was
used to correct the p values for multiplicity. The results
are expressed using p values and mean difference be-
tween groups with 95 % confidence intervals (95 % CI).
To find the most important cytokines to distinguish the
patient groups the random forests method was used
[28]. The cytokines were ordered using variable import-
ance, which is calculated by the mean decrease in the
Gini coefficient. Gini coefficient represents the contribu-
tion of each cytokine to the homogeneity of the results
of random forests. The higher the variable importance is
the better the cytokine is able to discriminate the
groups. The distributions of different patient groups of
nine cytokines with the best variable importance were
presented using box-plots.
Paired samples t test was used to test the difference in
cytokine concentrations before and after treatment in
LNB patients. Logarithmic transformation was made for
the data. The results are expressed using p values and
mean of difference between the measurements (before-
after) with 95 % confidence intervals (95 % CI). Nine cy-
tokines with the smallest p values were presented using
box-plots. The control group was added to these box-
plot figures as well to illustrate the difference with
controls although this group was not included in the
analyses.
In all of the analyses of cytokines, the natural logarith-
mic transformation was used to achieve the normality of
the distributions and all of the results and figures are pre-
sented using transformed variables. p values less than 0.05
were considered as statistically significant. Statistical ana-
lyses were carried out using SAS System for Windows,
version 9.4 (SAS Institute Inc., Cary, NC; USA), and all
figures were drawn with R 3.0.2 or 3.2.4 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Demographic features of patients
The demographic features of the patients are presented in
Table 2. The age of LNB patients varied from two to 82,
with the median age being 54. Median ages of the non-
LNB control patients, TBE patients, and MS patients were
56 (range 17–78), 62.5 (range 18–80), and 33 (range 21–
72), respectively. Male patients were dominant in the LNB
(65 %, n = 28), TBE (67 %, n = 12) and non-LNB control
patient (63 %, n = 12) groups while there were more fe-
male (77 %, n = 24) than male patients in the MS group.
Nevertheless, there was no statistically significant differ-
ence in the distribution of age (p = 0.817) or the sex ratio
(p = 0.741) between the groups.
Specific cytokine profiles distinguish the patient groups
from each other
The main goal of this study was to characterize the ex-
pression profile of a large panel of different cytokines in
the CSF of LNB patients and to compare the observed
profile to the cytokine levels of non-LNB controls and
patients suffering from other neurological conditions.
Cytokines IL-2 and IL-5 and chemokine CCL7/MCP-3
did not reach the detection limit of the multiplex assay
in the most of the measured samples, and thus, they
were excluded from further analyses. Nevertheless, sev-
eral other cytokines proved to be interesting in terms of
separating the LNB patients from the other study
groups. According to the variable importance (mean de-
crease in the Gini coefficient) calculated with the ran-
dom forests -method, the best nine markers to
distinguish all patient groups from each other were
CXCL13, IL-6, IL-10, G-CSF, IL-1ra, TNF-α, CXCL10,
IFN-γ, and IL-8 (Fig. 1).
Pairwise comparisons between the groups were made
to more closely analyze the differences in cytokine pro-
files of the groups. Specific cytokine profiles which were
able to discriminate the groups from each other were
detected, and the differences found were statistically sig-
nificant (Fig. 2, Additional file 1). Out of the 46 analyzed
cytokines, only ten (LIF, HGF, IL-1α, MIF, IL-2ra, SCGF-
b, IL-15, CCL2, M-CSF, TNF-β) were unable to


















The cytokine concentrations were analyzed with magnetic bead suspension
array using the Bio-Plex Pro Human Cytokine 21- and 27-plex panels
aThe concentrations of chemokine CXCL13 were analyzed with an
ELISA-based method
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distinguish LNB patients from the non-LNB controls
(Fig. 2a). Excluding these ten cytokines, all other studied
cytokines were significantly elevated in the CSF of LNB
patients when compared with the non-LNB controls.
Moreover, there were only ten cytokines (CCL2, LIF, IL-
15, M-CSF, IL-2ra, TNF-β, IL-4, HGF, IFN-α2, IL-17)
which were unable to separate LNB patients from MS
patients (Fig. 2b). LNB and TBE patients, on the other
hand, showed more similarities in their cytokine profile.
Yet, the levels of 15 cytokines were significantly different
between these two groups (Fig. 2c). The majority of
these 15 cytokines were more elevated in the CSF of
TBE patients when compared with LNB patients. Fur-
ther, TBE patients and MS patients were found to have
particular CSF cytokine profiles which were able to sep-
arate these groups from each other and from the non-
LNB controls (Additional file 1).
Cytokine profile as an indicator of immunopathogenesis
of the different conditions
Overall, TBE patients seemed to have the strongest in-
flammatory responses of all the groups analyzed. They
had elevated concentrations of all major T helper cell
type cytokines (Th1—e.g., TNF-α, IFN-γ/Th2—e.g., IL-4,
IL-6/Th9—e.g., IL-9/Th17—e.g., IL-17/Treg—e.g., IL-10)
in the CSF which indicates the involvement of many cell
types in the immune response. LNB patients also had
strong inflammatory responses and elevation of such cy-
tokines which suggest the activation of all the above
mentioned T cell types. There were two cytokines (IL-15
and LIF) which were elevated only in the CSF of TBE
patients but not in the CSF of LNB patients when com-
pared with non-LNB control patients (Additional file 2).
On the contrary, no cytokines which would have been
elevated in the CSF of LNB patients but not in the CSF
of TBE patients when compared with non-LNB controls
could be detected.
The concentrations of cytokines in the CSF of MS pa-
tients were not nearly as high as in the CSF of LNB and
TBE patients. However, also the cytokine profile of MS
patients suggests the involvement of Th1, Th2, and
Th17 cells in the inflammatory response. Chemokine
CCL2 and cytokine IL-1α were the only markers the
concentrations of which were significantly different in
the CSF of MS patients but not in the CSF of LNB or
TBE patients when compared with the non-LNB con-
trols (Additional file 2).
CXCL13 is a superior biomarker for LNB
Nine of the best cytokines to distinguish all patient
groups from each other according to the variable im-
portance (CXCL13, IL-6, IL-10, G-CSF, IL-1ra, TNF-α,
CXCL10, IFN-γ, and IL-8) are presented more in depth
(Fig. 3). Many statistically significant differences in the
levels of each of cytokine were found between the pa-
tient groups (Fig. 3, Additional file 2). However, the ma-
jority of the cytokines were the most elevated in the CSF
of the TBE patients. Indeed, out of the above mentioned
nine cytokines, cytokine IL-10 and chemokine CXCL13
were the only markers with a higher median concentra-
tion in the CSF on LNB patients when compared with
TBE patients. Importantly, CXCL13 was the only cyto-
kine whose concentration showed no overlap between
LNB (lowest value 460 pg/ml) and all other groups
(highest value 406.4 pg/ml) (Additional file 2).
In order to identify biomarkers of LNB treatment re-
sponse, we also evaluated the effect of antibiotic therapy
on the concentrations of different cytokines. Forty-two
of the cytokines analyzed were significantly different in
Table 2 Demographic features of the patients
LNB Non-LNB controls TBE MS
Median age 54 56 62.5 33
Age range 2–82 17–78 18–80 21–72
Male n = 28 (65 %) n = 12 (63 %) n = 12 (67 %) n = 7 (23 %)
Female n = 15 (35 %) n = 7 (37 %) n = 6 (33 %) n = 24 (77 %)
Fig. 1 The cytokines with the highest variable importance when
distinguishing patient groups from each other. Variable importance
is given by the mean decrease in the Gini coefficient, which
represents the contribution of each cytokine to the homogeneity of
the results of the random forests. The concentrations of all studied
cytokines in the CSF of patient groups (LNB, TBE, MS, and non-LNB
controls) were compared. Sixteen best cytokines to distinguish all
groups from each other are presented in the figure in descending
order. The higher the importance is, the better the respective
cytokine is able to discriminate the groups
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LNB patients after the antibiotic treatment when com-
pared with the situation before starting the treatment
(Fig. 4). As expected, all of these 42 cytokines were ele-
vated before the treatment and the levels declined statis-
tically significantly after the course of antibiotics.
According to this initial analysis, nine best markers are
presented more in depth in Fig. 5. CXCL13 and IL-1ra
were, based on the statistical analysis, the most useful
molecules as biomarkers of LNB treatment response
(Fig. 4, Fig. 5).
Discussion
The laboratory diagnostics of LNB is based on the CSF
lymphocytic pleocytosis and the detection of intrathecal
borrelia-specific antibody production. Although, in the
majority of cases, this approach is highly reliable, it has
certain drawbacks. First of all, antibodies are absent in
the early phase of the disease, and secondly, they may
persist in the CSF of LNB patients long after the anti-
biotic treatment [4]. Because of these limitations in the
antibody-based diagnostics of LNB, novel biomarkers for
the disease are required.
In recent years, chemokine CXCL13 has been intro-
duced as a new biomarker for LNB. The levels of
CXCL13 in the CSF of LNB patients are highly elevated
when compared with healthy controls or patients suffer-
ing from other neurological conditions [9–17]. Other
conditions where elevated CXCL13 levels can be
Fig. 2 Pairwise comparisons of cytokine concentrations (in logarithmic scale) in the CSF of LNB patients and other patient groups. Pairwise comparisons
between LNB patients and non-LNB controls, MS patients, and TBE patients were made using independent samples t test and Bonferroni’s method was
used to adjust the p values. The cytokines were placed in order according to calculated p values. Difference of means between the patient groups with
95 % confidence intervals are presented for all of the cytokines. The vertical lines in each panel separate statistically significant differences (p< 0.05) and not
significant differences (n.s.). a Comparison of LNB patients and non-LNB controls. b Comparison of LNB patients and MS patients. c Comparison of LNB
patients and TBE patients
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detected include, for example, neurosyphilis and CNS
lymphoma [9, 10, 16, 29–32]. In addition to CXCL13,
the concentrations of around 30 other cytokines in the
CSF of LNB patients have previously been analyzed and
studied as biomarkers for LNB [6, 8, 18–22]. To comple-
ment the thus far described cytokine profiles, we per-
formed a multiplex analysis measuring the levels of 48
different cell signalling molecules in the CSF of LNB pa-
tients, non-LNB control patients, TBE patients, and MS
patients. The levels of 36 cytokines were significantly
higher in the CSF of LNB patients when compared with
the non-LNB control patient group. In addition, 15 cyto-
kines were able to discriminate LNB patients from TBE
patients and the levels of 36 cytokines were significantly
different in LNB patients when compared with MS pa-
tients. However, in spite of the statistical differences in
many of the cytokines between LNB patients and the
other patient groups, CXCL13 was the only molecule
which explicitly discriminated LNB patients from all
other study groups. This result is in accordance with
previous reports [9–16] and highlights the unique role
of CXCL13 as an LNB biomarker.
One of the aims of this study was to evaluate the ap-
plicability of different cytokines in the CSF as indicators
of antibiotic treatment response of LNB patients. Previ-
ously, it has been shown that the levels of six different
cytokines (IL-1β, IL-8/CXCL8, CXCL12, CXCL13,
CCL3, and CCL4) decline after the antibiotic treatment
[9, 13, 15, 21, 22]. In this study, we demonstrated that
the levels of not only these 6 cytokines but also of 36
other cytokines were significantly elevated in the CSF of
LNB patients when compared with the same patients
after the antibiotic treatment. In addition to CXCL13,
the concentration of which rapidly declines after treat-
ment, for example, IL-1ra appeared as a potential indica-
tor of antibiotic treatment response.
Fig. 3 Nine most powerful cytokines to distinguish all patient groups from each other. According to variable importances (mean decrease in the Gini
coefficient), nine most powerful cytokines to separate the patient groups from each other are presented more in depth. Cytokine concentrations in
the CSF are presented as picogram per milliliter on a logarithmic scale. p values represent statistical difference of the groups compared to LNB patients
(independent samples t test with Boferroni’s correction)
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At least 21 of the previously studied cytokines were
also included in our multiplex panel. The levels of IL-1/
IL-1β, IL-4, IL-6, IL-7, IL-8/CXCL8, IL-10, IL-12, IL-17,
IL-18, CXCL10, CXCL12, CCL3, CCL4, IFN-γ, TNF-α,
and GM-CSF have been shown to be elevated in the
CSF of LNB patients and our study confirms these re-
sults [6, 8, 16, 19–24]. IL-15, on the other hand, was one
of the cytokines which was not elevated in the CSF of
LNB patients. This result is also in line with previous
studies showing no difference between the IL-15 levels
of LNB patients and the control groups [23, 24]. Because
most of the results achieved in this study are supported
by previous publications, the technical validation of the
used multiplex analysis procedure is well supported.
One previous report demonstrates the elevation of
CCL2 in the CSF of children suffering from LNB when
compared with the controls [23]. However, CCL2 was
not elevated in the CSF of our LNB study patients whose
age varied between 2 and 82. Cytokine IL-13, on the
other hand, was elevated in the CSF of LNB patients in
this study, although a previous report has demonstrated
that this cytokine is not elevated in LNB children [23].
Thus, the age of the study subjects appears to have an
impact on the CSF cytokine concentrations. However,
no significant age or sex related differences in cytokine
concentrations were detected in this study. Two cyto-
kines, IL-5 and IL-2, which have previously been sug-
gested to be either elevated or downregulated in the CSF
of LNB patients [8, 19, 23, 24] did not reach the detec-
tion limit in the most of our study samples. The time
used for the transportation of the CSF samples to la-
boratories may vary considerably and, thus, lead to the
observed variation in cytokine concentrations between
different studies. In addition, variation between studies
could be explained by differences in the handling and
the storage of the CSF samples. However, overall our re-
sults demonstrate that, in addition to the previously
studied cytokines, there are at least 15 more cytokines
the levels of which are significantly different between the
CSF of LNB patients and the CSF of non-LNB control
patients.
One possible explanation for the differences found in
the CSF cytokine profiles between various studies might
be the distinct abilities of borrelia genospecies and
Fig. 4 Pairwise comparison (in logarithmic scale) of cytokine concentrations between LNB patients before and after antibiotic treatment.
Differences in cytokine concentrations before and after treatment in LNB patients were analyzed using paired samples t test. The cytokines were
placed in order according to calculated p values. The mean of difference between the measurements before and after treatment with 95 %
confidence interval is presented. The vertical line separates statistically significant differences (p < 0.05) and not significant (n.s.) differences
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strains to cause inflammation. For example, B. burgdor-
feri strains from Europe and the USA have been shown
to cause different inflammation patterns. When periph-
eral blood mononuclear cells were stimulated with vari-
ous B. burgdorferi strains, the US strains triggered
stronger immune response than the strains from Europe.
US strains induced higher levels of innate immune medi-
ators as well as Th1-associated cytokines. The strains
from Europe, on the other hand, induced stronger ex-
pression of Th17 cytokines when compared with the US
strains [33]. Thus, the cytokine profile of an individual
patient most probably depends, in addition to the im-
mune system of the infected individual, on which borre-
lia genospecies and strain caused the disease.
Concerning the immunopathogenesis of LNB, it has
been demonstrated that the CSF of LNB patients is char-
acterized by a lymphocytic pleocytosis and, notably, LNB
patients have more B cells in their CSF when compared
with the CSF of patients suffering from many other
neurological conditions [5, 7, 8]. Furthermore, chemo-
kine CXCL13, which was demonstrated to be superior as
a biomarker for LNB when compared with any other
cytokine analyzed, is a B cell chemoattractant [34]. This
suggests that B cells have an important role in the im-
munopathology of LNB. In addition, the CSF of LNB pa-
tients has been characterized by cytokines reflecting a
Th1 type immune response early in the infection which is
later accompanied by a Th2 type response [6]. Also, the in-
volvement of Th17 and Treg immune responses in the im-
munopathology of LNB has been suggested [6, 23, 24, 35].
In this study, we confirm that Th1, Th2, Th17, and Treg
immune responses are all involved in the immunopathol-
ogy of LNB as the signature cytokines of these responses
were elevated in the CSF of LNB patients when compared
Fig. 5 Nine most powerful cytokines as markers of antibiotic treatment response. According to analysis made in Fig. 4, nine best cytokines to
differentiate CSF samples of LNB patients after the antibiotic treatment from samples taken before the treatment are presented more in depth.
Cytokine concentrations in the CSF are presented as picogram per milliliter on a logarithmic scale
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with the non-LNB controls. Furthermore, this study is the
first report demonstrating IL-9 secretion in the CSF of LNB
patients which suggests that also the quite recently de-
scribed Th9 cells [36] are involved in the immunopathology
of LNB. This finding is supported by an in vitro study
which has previously demonstrated that the signature cyto-
kine of Th9 response, cytokine IL-9, can be produced by
borrelia stimulated macrophages [37].
A main symptom of LNB is painful meningoradiculitis
[4]. The cause of the pain has remained somewhat un-
ravelled. Cytokines IL-6, IL-8, and CCL2 have been asso-
ciated with the sensation of pain and proposed to be the
triggers of pain sensation in LNB [38, 39]. Also in our
study, LNB patients had elevated concentrations of IL-6
and IL-8 in their CSF when compared with the non-
LNB controls. However, also TBE patients had higher
concentrations of IL-6 and IL-8 in their CSF when
compared with non-LNB controls even though TBE is
not generally characterized by meningoradiculitis [40].
The concentration of IL-6 was even higher in TBE
patients when compared with LNB patients. This in-
dicates that there have to be some other mediators as
well which cause the pain sensation specifically in
LNB patients but not in TBE patients. Chemokine
CXCL13 has recently been linked to neuropathic pain
in a mouse model [41]. The concentration of CXCL13
in the CSF of LNB patients is significantly higher
when compared with non-LNB controls or TBE pa-
tients. Thus, CXCL13 might be one of the reasons
behind the sensation of pain of LNB patients. In the
future, it would be interesting to more closely analyze
the role of CXCL13 as the causative agent of the pain
sensation in LNB patients. In fact, we are conducting
a clinical study where LNB patients evaluate their
subjective sensation of pain on a specific scale before
and after antibiotic treatment. The concentration of
CXCL13 in the CSF of these patients will also be
measured prior and after the treatment to analyze the
correlation between CSF CXCL13 concentration and
the sensation of pain.
Conclusions
In this study, we demonstrated that there were signifi-
cant differences in the CSF cytokine profiles of LNB,
non-LNB, TBE, and MS patients. Yet, chemokine
CXCL13 clearly differentiated LNB patients from other
study groups the best with the highest variable import-
ance and the biggest difference of means when com-
pared with the other patient groups. This result
highlights the uniqueness of CXCL13 as a biomarker of
LNB. In addition, we demonstrated that, in addition to B
cells, all major T helper cell types are involved in the
immunopathogenesis of LNB.
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Additional file 1: Pairwise comparisons of cytokine concentrations
(in logarithmic scale) in the CSF of TBE, MS, and non-LNB patients. Pairwise
comparisons were made between TBE, MS, and non-LNB patient groups
using independent samples t test and Bonferroni’s method was used to
adjust the p values. The cytokines were placed in order according to
calculated p values. Difference of means between the patient groups with
95 % confidence intervals are presented for all of the cytokines The vertical
lines in each panel separate statistically significant differences (p < 0.05) and
not significant (n.s.) differences. (A) Comparison of MS patients and TBE
patients. (B) Comparison of non-LNB controls and MS patients. (C)
Comparison of non-LNB controls and TBE patients. (DOCX 326 kb)
Additional file 2: CSF cytokine concentrations in LNB, non-LNB, TBE, and
MS patients. The median concentrations and ranges of each measured
cytokine in the CSF of different patient groups are presented. Also the
p values of statistical analyses (independent samples t test with Boferroni’s
correction) of each studied cytokine are shown. (DOCX 22 kb)
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homodimer; ra: Receptor antagonist; SCF: Stem cell factor; SCGF-β: Stem cell
growth factor β; TBE: Tick-borne encephalitis; TNF: Tumor necrosis factor;
TRAIL: TNF-related apoptosis-inducing ligand; VEGF: Vascular endothelial growth
factor; β-NGF: β nerve growth factor
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